Advice

following a full submission for an end of life and orphan medicine:
 
polatuzumab vedotin (Polivy®) is accepted for use within NHSScotland on an interim basis subject to ongoing evaluation and future reassessment.

Indication under review: in combination with bendamustine and rituximab for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for haematopoietic stem cell transplant.

In a phase Ib/II study polatuzumab vedotin in combination with bendamustine and rituximab significantly increased complete response rate compared to bendamustine and rituximab alone.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.

Medicine details

Medicine name:
polatuzumab vedotin (Polivy)
SMC ID:
SMC2282
Indication:

In combination with bendamustine and rituximab for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant.

Pharmaceutical company
Roche
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Interim acceptance
Date advice published
07 September 2020